Hand holding a risankizumab autoinjector pen. Marketed as Skyrizi, Risankizumab is a humanised monoclonal antibody that binds to interleukin 23A (IL-23A) and blocks the activity of pro-inflammatory cytokines. Risankizumab is used to treat moderate to severe plaque psoriasis and active psoriatic arthritis. | |
Licence : | Droits gérés |
Crédit: | Science Photo Library / Marazzi, Dr. P. |
Taille de l’image : | 8256 px × 5504 px |
Model Release : | Non requis |
Property Release : | Non requis |
Restrictions : |
|